Optimi Health Corp. · CSE:OPTI
Optimi Health — Investor Presentation (September 2026)
22 slides from Optimi Health's investor presentation, September 2026
Slide 1: The direct-to-clinic psychedelic drug manufacturer
Optimi Health Corp. I N V E S T O R P R E S E N T AT I O N SEPTEMBER 2026 The direct-to-clinic psychedelic drug manufacturer NASDAQ: OPTH
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements This presentation has been prepared by Optimi Health Corp. ("Optimi" or the "Company") for informational purposes only. It is based entirely on publicly available information, including the Company’s public filings with applicable securities regulators, press
Slide 3: Investment highlights
WHY OPTIMI Investment highlights Commercial today with early- Advancing clinical drug Vertically integrated with mover advantage development pipeline licensed & GMP-certified facility • One of few companies supplying both cGMP • Two Health Canada-authorized clinical trials • Health Canada Drug Estab
Slide 4: Supplying patients today
WHO WE ARE Supplying patients today • COMPANY SNAPSHOT I ncorporated: 2020 in Well-positioned to quickly leverage the rescheduling British Columbia environment shaping the markets of tomorrow • Uplisted: N asdaq May 2026 • Ver tically integr ated NATURAL NATURAL 20,000 sq ft cGMP footprint Psilocybi
Slide 5: Chronic, costly unmet needs
THE NEED Chronic, costly unmet needs Legacy options including SSRIs, benzodiazepines and psychotherapy have limited efficacy and high relapse rates 100M+ $232B $540B TRD WORLDWIDE1 US ANNUAL PTSD BURDEN (2018)2 US PROJECTED DEPRESSION COST/YR BY 20303 🇦🇺 🇨🇦 🇺🇸 Australia Canada United States…
Slide 6: Psilocybin
PSILOCYBIN CAPSULES & DISTRIBUTION Psilocybin Optimi's proprietary natural psilocybin extract capsule is already reaching patients in Australia W H AT I S P S I L O C Y B I N ? § Naturally occurring psychedelic compound found in certain fungi, known for inducing neuroplasticity and resetting dysfunc
Slide 7: MDMA
MDMA CAPSULES & DISTRIBUTION MDMA Global MDMA access is accelerating Optimi is actively supplying patients in Australia and Canada, with hundreds treated to date WH AT I S M D M A ? § Psychoactive compound that enhances emotional processing, reduces fear responses, and strengthens therapeutic connec
Slide 8: Pipeline: clinical path to registration
REGULATORY PATH Pipeline: clinical path to registration Program Indication Phase 1 Phase 2 Phase 3 Overview Phase 2 Clinical Trial Single supervised session combining natural psilocybin and psychotherapy Participants: Up to 200 Natural Psilocybin MDD Sites: Multiple sites in Canada Primary efficacy
Slide 9: Vertically integrated cGMP manufacturing
HOW WE MAKE IT Vertically integrated cGMP manufacturing Cultivation & sourcing Extraction & API Formulation QC & release Export & dispensing Sterile cultivation of Natural psilocybin Dose-titrated HPLC-MS verification, USP International narcotic Psilocybe species; › extraction with › encapsulation a
Slide 10: An established commercial process
DIRECT-TO-CLINIC MODEL An established commercial process As w i t h ketamine and cannabis, the global MDMA & psilocybin mar ket s may emerge through rescheduling and driven by cost-efficient medicine, cGMP manufacturing, and scalable direct-to-clinic distribution, subject to applicable regulatory re
Slide 11: Optimi in Australia
PROOF OF MODEL Optimi in Australia Nearly 5,000 doses shipped as of 1Q 2026 Repeat orders scaling with distribution partners in Australia Capacity to manufacture millions of doses for export 01 02 03 04 Optimi exports from Local pharmacy Patient receives Payors reimburses Canada t o Australia delive
Slide 12: Global rescheduling is underway
WHAT DOES RESCHEDULING MEAN? Global rescheduling is underway Rescheduling is a government classification that determines whether a drug has accepted medical use(s) B E F OR E R E S C H E D U L I N G · S C H E D U L E I A F T E R R E S C H E D U L I N G1 · S C H E D U L E I I / I I I Restricted Unloc
Slide 13: Positive US signals
POSITIVE US SIGNALS "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life" President Donald J. Trump statement on April 18, 2026, while signing an executive order to fast-track research, testing, and reg
Slide 14: An inflection year for regulated psychedelics
INDUSTRY DEVELOPMENTS An inflection year for regulated psychedelics Jan 1 Apr 18 Jun 16 Sep 14 Czech Republic US Executive Order: Bill C-286 ("Thomas’ Bill") US FDA public hearing on formally reschedules priority vouchers, Right to introduced — regulated the potential future psilocybin for medical T
Slide 15: Global regulated access is compounding
WHAT’S NEXT Global regulated access is compounding Jurisdiction Framework Status Optimi position Australia TGA Authorised Prescriber Scheme (2023) Active (commercial) Supplying both MDMA & psilocybin since 2024/25 Canada Special Access Program · s.56 · trials Active (limited) Domestic cGMP supplier;
Slide 16: Competitive landscape
COMPETITIVE LANDSCAPE Optimi Commercial-stage psychedelics company, with two drugs in market and the license to manufacture botanical and generic versions. Company Stage of Lead Program Molecule Indication § Commercial in Australia § Natural psilocybin § Treatment-resistant depression § MDMA § PTSD
Slide 17: Ability to thrive in various scenarios
STRATEGIC POSITION Ability to thrive in various scenarios 1 FDA approves a psilocybin drug (2026–27 window) 2 FDA approvals slip § Approval triggers DEA rescheduling under the EO § Current model business continues § U.S. clinic infrastructure builds out § Australia expands, Canada’s SAP growth conti
Slide 18: Accomplishments & catalysts
MOMENTUM Accomplishments & catalysts DELIVERED IN 2026 TO DATE CATALYSTS AHEAD § First 2026 production of MDMA & psilocybin; Australian import § Continue Australian expansion under the broadened prescriber permits framework § MDMA + psilocybin exports; first MDMA-assisted treatments § Begin enrollme
Slide 19: Executive management
EXPERIENCED TEAM Executive management Executives, directors, and strategic advisors who built and scaled global consumer and pharmaceutical brands Strategic Advisors Chip Wilson NASDAQ: LULU | NYSE: AS Founder of Lululemon Athletica (NASDAQ: LULU); largest individual shareholder of Amer JJ Wilson Da
Slide 20: Financial Highlights & Ownership
CAPITAL EFFICIENCY Financial Highlights & Ownership Capital efficient model SUPPLYING CLINICS IN AUSTRALIA $9.2M Cash balance Target: June 30, 2026 100 ~$30M Capital raised to date since founding 26 ~17% Directors and June 2026A Early 2027 Estimate Executive Officers beneficial ownership 20
Slide 21: Why Optimi
INVESTMENT SUMMARY Why Optimi The trusted manufacturer for emerging psychedelic-based mental health treatments Commercial today Path to registration § Revenue since 2Q 2024 § Health Canada-authorized clinical trials § ~5,000 doses shipped globally § Phase 2: Natural psilocybin § UK clinical supply a
Slide 22: Thank you
Optimi Health NASDAQ: OPTH T HA NK Y O U The direct-to-clinic psychedelic drug manufacturer IN V E S T O R R E L A T I O N S CORE IR ir@optimi.net optimihealth.net
Optimi Health — Investor Presentation (September 2026) on 6ix